Over the past 15 years, a wealth of information has been published on transcripts and proteins 'induced' (requiring new protein synthesis) in mammalian cells after ionizing radiation (IR) exposure. Many of these studies have also attempted to elucidate the transcription factors that are 'activated' (i.e., not requiring de novo synthesis) in specific cells by IR. Unfortunately, all too often this information has been obtained using supralethal doses of IR, with investigators assuming that induction of these proteins, or activation of corresponding transcription factors, can be 'extrapolated' to low-dose IR exposures. This review focuses on what is known at the molecular level about transcription factors induced at clinically relevant (p2 Gy) doses of IR. A review of the literature demonstrates that extrapolation from high doses of IR to low doses of IR is inaccurate for most transcription factors and most IR-inducible transcripts/proteins, and that induction of transactivating proteins at low doses must be empirically derived. The signal transduction pathways stimulated after high versus low doses of IR, which act to transactivate certain transcription factors in the cell, will be discussed. To date, only three transcription factors appear to be responsive (i.e. activated) after physiological doses (doses wherein cells survive or recover) of IR. These are p53, nuclear factor kappa B(NF-jB), and the SP1-related retinoblastoma control proteins (RCPs). Clearly, more information on transcription factors and proteins induced in mammalian cells at clinically or environmentally relevant doses of IR is needed to understand the role of these stress responses in cancer susceptibility/resistance and radio-sensitivity/resistance mechanisms.
Ionizing radiation (IR)-inducible responses in mammalian cells
Ionizing radiation exposure of mammalian cells causes a spectrum of lesions within the cell. At the DNA level, these lesions include DNA single-and double-strand breaks (SSBs, DSBs, respectively), DNA base damage and apyrimidinic/apurinic (AP) sites, and DNA-protein crosslinks. Although the most important lesion for triggering cell death responses is the formation of DSBs, other DNA lesions (e.g. formation of 8-hydroxyguanine) may have dramatic mutagenic, and thereby carcinogenic, consequences (Wallace, 2002) . Aside from DNA damage, IR also causes a spectrum of other lesions in cellular macromolecules (e.g. lipid peroxidation) due to reactive oxygen species (ROSs) created by the ionization of water and iron-related Fenton reactions within the cell. Although these non-DNA lesions are probably not life-threatening to the cell, they can stimulate various signal transductions pathways (such as protein kinase C (PKC), JNK, ceramide, and MAPK activation) after certain doses of IR. Thus, IR causes a spectrum of DNA and non-DNA lesions that represent potential signals that activate sensory proteins (Davis et al., 1998b) . These sensory proteins act to signal that damage has occurred in the cell, as well as to regulate processes that both halt cell cycle progression and stimulate repair of DNA lesions.
Signals from DNA
At the DNA level, DNA damage sensors stimulated by IR include (a) the DNA-dependent protein kinase repair complex (DNA-PK, composed of Ku70, Ku80, and DNA-PK catalytic subunit (DNA-PKcs) (Jackson, 1996 (Jackson, , 1997 ; (b) the ataxia telengiectasia (AT)-mutated gene (ATM)/c-Abl complex (Barlow et al., 1996; Shiloh, 2001) ; (c) the ataxia telangiectasia-related gene (ATR) (Tibbetts et al., 1999 (Tibbetts et al., , 2000 ; (d) the NBS1-MRE-11-RAD50 complex (Carney et al., 1998) ; (e) the DNA mismatch repair complex (Davis et al., 1998a; Fishel, 1998 Fishel, , 2001 Kolodner, 1996) ; and (f) the RAD9-HUS1-RAD-1 (9 : 1 : 1) complex (Rauen et al., 2000; Burtelow et al., 2001; Lindsey-Boltz et al., 2001) , among others as yet to be defined processes within mammalian cells (see corresponding reviews of these processes in this issue of Oncogene). It is possible that many of these damage sensors exist in a huge complex, referred to as the BRCA-containing assembly complex (BASC complex), and are activated based on type and/or extent of DNA damage (Wang et al., 2000) .
These damage sensors not only play a role in DNA repair, but also simultaneously regulate cell cycle checkpoint responses that control life and death decisions. Eventually, the damage sensors stimulate specific signal transduction processes that activate specific transcription factors, such as SP1, p53, and NF-kB (see below). These activated transcription factors, in turn, control gene expression, cell cycle checkpoint regulation, and under severe conditions may stimulate apoptosis (Figure 1 ). In recent years, our knowledge of the circuitry of these pathways has increased dramatically, mostly from the development of sound genetic models. We are only now beginning to understand the significance of these pathways in cell cycle progression, apoptosis, survival, mutagenesis and carcinogenesis (particularly when these pathways are altered due to accumulated or inherited mutations). However, the promise of complete understanding of the retrograde signaling processes that emerge from DNA damage to cell cycle checkpoint control is tempered by the fact that much of our information has been obtained to date, using rather high (most times supra-lethal) doses of agents, such as IR. In this review, we will examine the transcription factors activated after IR, with particular emphasis on doses required for activation of these transcription factors. For our discussion, 'activation' refers to conversion of an inert protein to an active form that can stimulate transcription of a gene. Expression of the new transcript or protein as a result of the 'activation' of these transactivation factors is an 'induced' gene product, such as the growth arrest and damage inducible (GADD) gene products (Fornace et al., 1989) or Xray-induced transcripts/proteins (XIPs) (Boothman et al., 1993) . We will focus on the activation processes of transcription factors following low, clinically relevant doses of IR.
Signals from non-DNA targets
Much less is understood about IR-induced damage signaling from non-DNA targets that eventually cause transactivation of specific proteins (i.e. transcription factors) at clinically relevant doses of IR. Most of the studies attempting to elucidate these signaling events from non-DNA targets have utilized supralethal doses of IR and the triggering mechanisms have, in general, not been elucidated. Specifically, exposure of cells to IR results in a spectrum of lesions in cell membranes (e.g. lipid peroxidation). Lipid peroxidation can result in the activation of PKC, MAPKK, casein kinase, the ceramide pathway, JNK, ERK, and other signal transduction pathways. In this way, damage from cellular plasma membranes is signaled inward to activate specific transcription factors. In general, these pathways have not been evaluated at low doses of IR. The relevance of such signal transductions in the activation of specific transcription factors will be evaluated below for each known IR-stimulated transcription factor. Since IR causes simultaneous damage to DNA and non-DNA targets, it can be a daunting task to evaluate the relative strength of DNA versus non-DNA targets for triggering a given signal transduction process. This, in turn, makes it difficult to determine the consequences of a particular activated signal transduction and/or transcription factor pathway in the overall response of the cell to IR. In particular, the use of high doses of IR to stimulate signal transduction, transcription factor activation, cell cycle checkpoint, or apoptotic responses in a more rapid timeframe (a rationale used by many investigators for the use of supralethal IR doses) appears to create many simultaneous (and at times conflicting or synergistic) signals that are clearly not applicable to clinically relevant lower doses of IR. These issues will be addressed in our discussion of known IRactivated transcription factors below.
Known IR-activated transcription factors
A review of the literature indicates a fairly select number of transcription factors activated by IR at any dose tested and in a variety of cell models. This list includes p53, NF-kB, the retinoblastoma control proteins (RCPs), the early growth response 1 transcription factor (EGR-1, an SP1-like factor), the c-Fos/c-Jun AP-1 complex, and the octamer-binding protein-1 (Oct-1) transcription factor (Table 1) . The proteins listed in Table 1 represent the known transcription factors activated by IR, as found by a review of the current Figure 1 Sensors of DNA damage that simultaneously trigger signal transduction pathways that control cell cycle regulation, DNA repair and cellular recovery, and cell death responses in severely damaged mammalian cells after exposure to IR Induction of transcription factors after low doses of IR T Criswell et al literature.
In the sections to follow, we will discuss the data that demonstrate the IR activation of these transcription factors. We will then explore whether these transcription factors are activated at low clinically relevant doses of IR and discuss their proposed functional significance in IR responses in normal or tumor cells.
IR stimulation of p53 transcriptional responses
The p53 tumor suppressor gene is mutated in B50% of all human tumors and has been extensively reviewed (Vogelstein et al., 2000; Stewart and Pietenpol, 2001; Appella and Anderson, 2001) . This review will specifically focus on the activation and functions of p53 by IR. Most of the studies investigating these functions have been done at high doses of IR (44 Gy), while the role of p53 in low-dose responses still remains to be clarified. The p53 protein is tightly regulated and remains at low levels in unstressed cells (Prives and Hall, 1999) , but is rapidly stabilized by various types of cellular stresses, including ionizing (IR) and ultraviolet (UV) radiations, hypoxia, stabilization/destabilization of microtubules, and ribonucleotide depletion. In response to DNA damage, p53 is rapidly stabilized through post-translational modifications that may include phosphorylation, acetylation, sumolation, glycosylation, and ribosylation. In general, IR is believed to activate (stabilize) p53 mainly through phosphorylation by the ATM kinase (Abraham, 2001; Appella and Anderson, 2001; Wahl and Carr, 2001 ). p53 plays a critical role in maintaining genomic integrity after cellular stress by acting as a transcription factor for a number of downstream genes that may mediate either cell cycle arrest or apoptosis, thereby preventing propagation of damaged DNA. The response to p53 stabilization is cell-type-dependent, as well as damage-dependent. For example, epithelial cells tend to undergo growth arrest after IR exposure, whereas lymphoid cells tend to undergo p53-dependent apoptosis (Pettitt et al., 2001) . The signals that determine whether a cell undergoes cell cycle arrest or p53-dependent apoptosis after DNA damage still remain to be elucidated.
The p53 protein consists of four major domains, a transactivation domain at the N-terminus, a proline-rich domain, a DNA-binding domain and a carboxyterminal tetramerization domain (Unger et al., 1993; Wang et al., 1994) . The transactivation domain contains the MDM2 binding site (Oliner et al., 1993) , as well as binding sites for members of the transcription machinery. The proline-rich domain is thought to be important for efficient growth arrest after damage (Stewart and Pietenpol, 2001 ). p53 sequence-specific DNA binding occurs through the core DNA-binding domain (Bargonetti et al., 1993) . After stress-induced stabilization, p53 forms homotetramers that bind to two copies of a 10-base pair (bp) nucleotide sequence (5 0 -PuPuPuC(A/ T)(T/A)GPyPyPy-3 0 ) divided by a 0-13 bp spacer (el-Deiry et al., 1992) . The importance of p53 sequence-specific DNA binding is emphasized by the fact that most mutations found in human tumors within the p53 gene occur at 'hot spots' within this DNA-binding domain (Pavletich et al., 1993) . These mutations result in a dominant-negative form of the protein that can heterodimerize with wild-type p53 protein and disrupt its DNA binding, thus inhibit downstream gene activation. The C-terminal tetramerization domain is (as its name implies) responsible for tetramer formation, as well as for regulation of DNA binding by the core domain (Stewart and Pietenpol, 2001 ).
As mentioned above, p53 has a very short half-life in unstressed cells, and thus cellular protein levels are strictly regulated at low levels by a variety of mechanisms. The stability and activity of p53 can be influenced in several ways: (1) through ubiquitin-mediated proteolytic degradation; (2) through subcellular localization of the p53 protein; and (3) through allosteric regulation of the core DNA-binding domain by the C-terminal regulatory domain. In the first instance, the MDM2 protein, which acts as an E3 ubiquitin ligase for p53 (Honda et al., 1997; Fang et al., 2000; Michael and Oren, 2003) , binds to the N-terminus of p53 and results in its rapid degradation through the proteasome pathway. MDM2 also blocks p53 activity by binding to the region of the peptide required for transcriptional activation of downstream genes. p53 is a transcriptional activator of the MDM2 gene and thus generates a negative feedback loop that tightly controls the amount of p53 present within the cell. Induction of transcription factors after low doses of IR T Criswell et al Ser 46 are also phosphorylated within this domain and may enhance p53 stability as well as influence acetylation of the C-terminus (discussed below) (Appella and Anderson, 2001; Wahl and Carr, 2001) . Additionally, phosphorylation of MDM2 can also disrupt the interaction of these two proteins and result in stabilization of p53 (Mayo et al., 1997) .
For p53 to bind DNA and act as a transcription factor, the stabilized protein must be localized to the nucleus. In this fashion, activation of p53 can be regulated through its subcellular localization. p53 contains a nuclear localization sequence and a nuclear export sequence within its carboxy-terminal domain. Moll et al. (1992 Moll et al. ( , 1995 demonstrated that in certain breast cancer and undifferentiated neuroblastoma cell lines, p53 is inactivated by sequestration in the cytoplasm. MDM2 may also act to export p53 out of the nucleus (Roth et al., 1998) , in addition to its ability to mediate p53 degradation.
The carboxy terminus of the p53 protein acts as an allosteric regulator of sequence-specific DNA binding. This was demonstrated initially by Hupp et al. (1992) using a bacterially expressed protein. Recombinant bacterial p53 bound poorly to DNA, and binding could be enhanced by the addition of antibodies specific to the C-terminal region of the protein. Phosphorylation of Ser 315 and Ser 392 within this domain also enhance sequence-specific DNA binding. Dephosphorylation of Ser 376 of p53 after IR allows the association of 14-3-3 proteins with the C terminus of the protein (Waterman et al., 1998) . Stavridi et al. (2001) demonstrate that this interaction is required for p53 to activate the downstream gene, p21 waf1/cip1 , and for the G 1 cell cycle checkpoint arrest response. Interestingly, this dephosphorylation event seems to be ATM-dependent, possibly by a phosphatase that is activated by ATM after IR (Waterman et al., 1998) . p53 also binds nonspecifically to short single-stranded DNA fragments through its carboxy-terminal domain, and this binding may enhance sequence-specific DNA binding, thus providing a potential role for p53 in DNA repair after damage. However, the significance of p53 associating with single-stranded DNA is not known.
In addition to phosphorylation, the C-terminal domain of p53 can also be acetylated and sumolated in response to DNA damage. Acetylation and sumolation both result in an increase in the transactivation ability of p53 and may account for this finding. In vivo, IR induces the acetylation of p53 at Lys 320 by PCAF and Lys 382 by CBP/p300. Acetylation at these sites is dependent on N-terminal phosphorylation at Ser 15 and to a lesser extent on phosphorylation at Ser 6 , Ser
9
, and Thr 18 Wahl and Carr, 2001 ). All of these phosphorylation events are ATM-dependent, although only Ser 15 has been shown to be phosphorylated directly by ATM. Sumolation occurs at Lys 386 after DNA damage (Muller et al., 2000) . Sumolation refers to the covalent attachment of a small ubiquitin-like molecule (SUMO-1) to Lys residues, but in contrast to ubiquitination, does not result in proteolytic degradation. The significance of sumolation after IR still remains to be elucidated.
p53 stabilization by IR
The signal upstream of p53 stabilization and activation after IR exposure most likely originate from DNA DSBs. This is supported by the fact that the kinases implicated in the phosphorylation of p53 are also implicated in DSB repair. These include two kinases that belong to the PI-3 kinase family, DNA-PK and ATM (see above), and indirectly, the checkpoint kinase 2 (Chk2). Ser 15 of p53 was identified as a substrate for DNA-PK in vitro (Lees-Miller et al., 1992) . Since DNA-PK is required for DSB repair in mammalian cells after IR exposure and since this residue falls within the MDM2-binding domain of the protein, this was an attractive model of p53 stabilization after IR. However, several recent reports have shown that Ser 15 of p53 is phosphorylated in cells deficient in DNA-PK and that p53 accumulation in these cells is capable of generating cell cycle arrest or apoptosis after IR Araki et al., 1999; Jimenez et al., 1999) . ATM is another kinase that has been shown to phosphorylate Ser 15 in response to DNA damage induced by IR in vitro (Banin et al., 1998; Canman et al., 1998) . In contrast to DNA-PK-deficient cells, AT lymphoblasts that lack the ATM gene have a decreased ability to generate p53-dependent cell cycle arrest or apoptosis after IR, suggesting an important role for ATM in generating these responses in vivo. Additionally, ATM has been implicated in phosphorylating Ser 9 and Ser 46 directly and Ser 20 indirectly through Chk2 (Ahn et al., 2000; Hirao et al., 2000) . Interestingly, ATM has also been implicated as the kinase that phosphorylates MDM2, thus disrupting the p53-MDM2 interaction by phosphorylation of both of these proteins.
p53 target genes
As mentioned previously, downstream target genes of p53 can be grouped generally into those required for growth arrest and those required for p53-dependent apoptosis (Stewart and Pietenpol, 2001 ). p21 waf1/cip1 , 14-3-3s, and GADD45 are three genes that are activated by p53 after IR and that are involved in growth arrest. p53 directly transactivates the p21 waf1/cip1 gene, which is an inhibitor of cyclin-dependent kinases (CKSs). By inhibiting CDKs, p21 blocks the cell cycle at the G 1 -S transition, as well as the G 2 -mitosis transition. Additionally, p53 can block cells in the G 2 transition through its activation of the 14-3-3s gene, which sequesters proteins required for entry into mitosis in the cytoplasm. GADD45 interacts with the repair protein, PCNA, and inhibits the entry of cells into S phase. It is important to note that the studies identifying these genes as targets of p53 transactivation were done with high doses of IR. It has been shown that p21 waf1/cip1 and GADD45 are induced after low-dose IR exposure (42 cGy) (Fornace et al., 2002) , but the exact role of p53 in this induction is not known.
p53-activated genes involved in IR-induced apoptosis are less clear and appear to vary with cell type. BAX was the first apoptotic gene identified that was transactivated by p53 and has been implicated in IR-induced apoptosis in testicular germ cell lines (Burger et al., 1998; EmbreeKu et al., 2002; Fei et al. 2002) , describe the tissuespecific induction of several p53-dependent apoptotic genes (KILLER/DR5, BID, PUMA, NOXA) after 5 Gy total body irradiation. Other groups have also investigated the transactivation of apoptotic genes after highdose IR Fei et al., 2002; Takai et al., 2002) , but little is known about the p53-dependent activation of these genes after clinically relevant doses.
IR stimulation of NF-jB responses
NF-kB is a transcription factor that exists as a latent form in association with the inhibitory protein, IkB. It was first discovered as a nuclear factor that bound to the kB element present in the immunoglobulin kappa light chain gene in 1986 (Sen and Baltimore, 1986) . It soon became apparent that it exists in most mammalian cell types as an inducible complex sequestered in the cytoplasm (reviewed by Miyamoto and Verma, 1995; Verma et al., 1995) . Many signaling pathways are known to cause degradation of IkB to release free NFkB that then migrates into the nucleus and regulates induction of a wide variety of genes through decameric kB-binding sites. NF-kB target genes are known to play roles in a diverse array of cellular and physiological functions, including apoptosis, proliferation, cell adhesion, migration, inflammatory and adaptive immune responses (reviewed in Ghosh et al., 1998; Karin and Ben-Neriah, 2000; Silverman and Maniatis, 2001; Ghosh and Karin, 2002) . While most studies focusing on the activation mechanisms and functional significance of NF-kB involve the use of proinflammatory cytokines, such as tumor necrosis factor-a (TNF-a) and IL-1, NF-kB has also been known to be activated by IR (Brach et al., 1991) . Using electrophoretic mobility shift assays (EMSAs) to detect newly liberated nuclear NFkB, the above group showed that an IR dose as low as 2 Gy was sufficient to activate NF-kB in the KG-1 human myeloid cell line, with the peak dose at 5-20 Gy and the peak time around 2-4 h after irradiation (Brach et al., 1993) . Like in many other NF-kB activation pathways known, a protein synthesis inhibitor did not prevent this activation pathway, indicating that de novo protein synthesis was not required. Since the above report, NF-kB activation by IR has also been observed in different cell systems (see below).
The IR doses required for maximal NF-kB activation vary greatly depending on the cell lines or systems analysed. In the EBV-transformed 244B human lymphoblastoid cell line, as in the case for the activation of AP-1 (see below), 0.5 Gy of IR was shown to yield maximal NF-kB activation (Sahijdak et al., 1994) . In the U1-Mel human melanoma cell line, 3-4.5 Gy was optimum with higher doses giving reduced activation (Sahijdak et al., 1994; Yang et al., 2000) . By contrast, in human diploid fibroblasts, doses as high as 20 Gy failed to activate NF-kB (Ashburner et al., 1999) . More complicating are the contrasting observations of NFkB activation following whole body irradiation at different IR doses. Zhou et al. (1999) reported that NF-kB activation by IR (8.5 Gy) is tissue-specific and only detectable in bone marrow, lymph nodes, and spleen. In contrast, Li and Karin (1999) demonstrated the activation of NF-kB in liver and kidney when mice were exposed to 20 Gy of IR. In cerebral cortex of Sprague-Dawley rats, NF-kB activation was detectable at 5 Gy with a steady increase up to 30 Gy (Raju et al., 2000) . It appears that different normal tissues possess differential IR sensitivity toward the activation of NFkB in vivo. However, it is presently unknown whether lower, more clinically relevant doses of IR (p2 Gy) would also yield activation of NF-kB in these normal tissues. Since NF-kB activation by IR can be readily observed in different human cancer cell lines derived from various tissue types in vitro (see below), but not normal counterparts (S Miyamoto, unpublished observations), it is intriguing to consider the possibility that transformation or carcinogenic events may sensitize cells to IR for activation of NF-kB. Ashburner et al. (1999) found that immortalization of human fibroblasts by SV40 was correlated with acquisition of NF-kB activation capacity following IR treatment, further supporting this idea. Thus, it is possible, and even likely, that cancer cells display higher sensitivity to IR for activation of NF-kB in vivo, when compared to normal counterparts.
While activation of NF-kB can be affected by tissue types and transformed states, in those systems where NF-kB activation by IR can be readily observed distinct molecular components and signaling events have been implicated under different experimental settings. These include protein tyrosine kinases (PTKs), PKC, ROS, RAS, ATM, DNA-PK, IkB kinase (IKK), and the ubiquitin-proteasome pathway (Figure 2 ). Of particular interest with regard to the mechanism of activation of NF-kB by IR is the possibility that nuclear DNA damage may be directly involved in the activation of the cytoplasmic NF-kB/IkB complex, that is, a novel nuclear-to-cytoplasmic, retrograde signaling pathway. Huang et al. (2000) demonstrated multiple lines of evidence for the existence of such a signaling pathway induced by another anticancer agent, camptothecin. IR is known to cause DSBs and subsequently activate nuclear kinases, such as ATM (reviewed in Zhou and Elledge, 2000) . ATM was critical for NF-kB activation by IR at 20 Gy using an ATM À/À mouse model, and the kinase inhibitor wortmannin prevented such activation (Li et al., 2001) . However, the requirement of ATM in NF-kB activation seems to be different at different IR doses. Earlier work by Jung et al. (1995 Jung et al. ( , 1997 showed that NF-kB activation in the SV40-immortalized AT5-BIVA human fibroblast cell line was still observed in these ATM-deficient cells exposed at 6 Gy of IR. However, the same group reported that ATM was required for IkB degradation, nuclear translocation of NF-kB and transcriptional activation by NF-kB in the same cell systems upon exposure to 20 Gy of IR (Lee et al., 1998) . Thus, the contribution of ATM is apparently dependent on the dose of IR in this cell system. Moreover, the general role of ATM has been challenged by Ashburner et al. (1999) , since neither AT nor wild-type human diploid fibroblasts (not immortalized by SV40) activated NF-kB. Similarly, while another nuclear ATM-related kinase, DNA-PK, has been implicated in the activation of NF-kB after 10 Gy exposure of HeLa cervical carcinoma and M059 K glioma cell lines (Basu et al., 1998) , liver and kidney tissues from DNA-PKcs, Ku70, and Ku80 knockout mice displayed no NF-kB activation defects when exposed to IR at 20 Gy (Li et al., 2001) . In the latter report, c-ABL was also found dispensable for this activation pathway at this high dose of radiation. Moreover, there are conflicting results regarding the role of the IkB kinase complex, phosphorylation and degradation of IkB by the ubiquitin-proteasome pathway to release active NF-kB when cells are exposed to different doses of IR in different cell systems (Raju et al., 1998; Curry et al., 1999; Miyakoshi and Yagi, 2000; Li et al., 2001; Shao et al., 2001; . While direct phosphorylation of IkB by both ATM and DNA-PK has been shown in vitro (Jung et al., 1997; Basu et al., 1998; Lee et al., 1998) , whether such a direct phosphorylation is indeed induced by IR in intact cells has not been established. Thus, it is presently unclear whether nuclear DSBs are indeed required for activation of NF-kB by IR, especially at clinically relevant doses.
A previous study mentioned above (Brach et al., 1991) implicated the involvement of PKC based on the effect seen with H7 inhibitor and downregulation of PKC by prolonged TPA treatments. Similarly, using the human Ramos B cell line exposed to IR doses of 10-40 Gy, Uckun et al. (1993) have implicated the involvement of PTKs and possibly PKC in the activation of NF-kB. However, by comparing the kinetics and magnitudes of NF-kB responses in primary tonsillar B cells exposed to TPA versus 15 Gy of IR, Wilson et al. (1993) concluded that simple PKC activation is unlikely to account for this activation process. Uckun et al. (1993) also suggested that the generation of ROSs might be upstream of PTK activation. ROSs were previously proposed to represent a common second messenger for NF-kB activation by distinct signaling agents (Schreck et al., 1992) . Consistently, antioxidants (e.g. N-acetylcysteine (NAC)) have been shown to prevent NF-kB activation by IR in several cell lines exposed to a dose range of IR (0.5-30 Gy) (Mohan and Meltz, 1994; Baeuml et al., 1997; Iwanaga et al., 1998) . However, accumulating evidence indicates that the role of ROSs in NF-kB activation is also cell-type-restricted (reviewed by Janssen et al., 1993; Li and Karin, 1999; JanssenHeininger et al., 2000; Schoonbroodt and Piette, 2000) , and NAC can directly inhibit 26S proteasome activity that is essential for degradation of IkB to release free NF-kB (Pajonk et al., 2002) . Moreover, the site of IkBa degradation induced by IR can also be distinct from those induced by cytokines, since it was suggested to occur at the plasma membrane, rather than in the cytosol, in U251 glioblastoma cell line exposed at 10 Gy . The same group also indicated the involvement of the Ras signaling pathway in NF-kB activation by IR through the use of a recombinant adenoviral system that expresses the antiRas single-chain antibody fragment . Thus, there is the possibility that the activation of NF-kB may occur at the level of the plasma membrane at high doses of IR exposure. The upstream regulators, or how the Ras pathway, connects with NFkB activation following IR exposure is not well defined yet. It is also unclear whether lower doses (p2 Gy) of IR also employ the same activation mechanism to release NF-kB in the above or other cell systems.
Putting these published observations together, it is apparent that there is no consensus on the activation mechanism for IR regulation of NF-kB activity, especially at clinically relevant doses of IR. It is unclear whether IR-induced DSBs represent the signal initiating events or whether other stresses (e.g. ROSs) mediate this activation pathway. Different IR doses seem to invoke More complicating is the undetectable nature of NF-kB activation in many normal tissues after whole body irradiation, even at a relatively high dose of IR (up to 8.5 Gy). Many diploid human, normal cell types are also refractory to NF-kB activation following IR treatment in vitro, even though TNF-a can efficiently activate NFkB in these cells. These observations contrast with findings that many human cancer cell lines derived from different tissue types are permissive for activation of NF-kB by IR exposure in vitro. It is, however, important to note that NF-kB activation was measured by EMSAs in most of these studies. Recent studies indicate that NF-kB activation, as measured by reporter gene activation, can take place without an apparent increase in the NF-kB DNA-binding activity (Finco et al., 1997) . Further in-depth analyses of signaling pathways and differential IR sensitivity of human normal versus cancerous cell types for activation of NF-kB are, therefore, warranted.
What is the role of NF-kB activation in biological response to IR? An earlier study showed that induction of IL-6 by 5 Gy of IR exposure of FH109 human embryonic fibroblast cell line was dependent on the kBbinding site present in its promoter (Brach et al., 1993) . Others found a similar observation in PC-12 rat pheochromocytoma (Abeyama et al., 1995) and HeLa cell lines (Beetz et al., 2000) . IL-6 is critical for acute inflammatory reactions seen in IR-treated tissues. TNFa, IL-1a, IL-1b, intercellular adhesion molecule-1 (ICAM-1), and E-selectin are also critical for inflammatory responses. Zhou et al. (2001) found that induction of TNF-a, IL-1a, IL-1b and IL-6 in spleen, mesenteric lymph nodes, and bone marrow of Balb/c mice following exposure to 8.5 Gy of IR was significantly reduced in mice knocked out for the p50 subunit of NF-kB. Studies also indicated that ICAM-1 induction by IR in HeLa, HaCaT keratinocyte line, human umbilical vein endothelial cells (HUVECs), and microvascular endothelial cells depends on NF-kB activation (Baeuml et al., 1997; Hallahan et al., 1998) . Similarly, Eselectin induction by IR (0.5-10 Gy) was also found to depend on activation of NF-kB in HUVECs (Hallahan et al., 1995a) . All of these genes possess kB sites in their promoters (reviewed in Ghosh et al., 1998) . Thus, there is a consensus that the synthesis of inflammatory cytokines and molecules following IR exposure is coordinated by the activation of NF-kB in both in vitro and in vivo situations.
Another important role of NF-kB in biological response to IR is the modulation of radiosensitivity. An earlier study showed that the radiosensitive phenotype of SV40-immortalized AT5BIVA cells exposed to 6 Gy of IR was reversed by the expression of an Nterminally truncated I kB that inhibited constitutive NFkB activity present in these cells (Jung et al., 1995) . These studies suggested that NF-kB promoted radiosensitivity. The similar radiosensitizing role of NF-kB inhibition has been observed in the human MRCA5CV1 fibroblast line exposed to 5 Gy and U1-Mel cells exposed at the dose range of 5-15 Gy (Yang et al., 2000) . In contrast, Wang et al. (1996) showed that when the HT1080 fibrosarcoma cell line was treated with IR, inhibition of NF-kB activation by the stable expression of the 'super-repressor' IkB mutant caused significant radiosensitization, as measured by the colony-formation assay at doses of 5 and 10 Gy (but not at 2.5 Gy). This latter study indicated that NF-kB activation caused radioresistance, rather than radiosensitization. This finding has also been confirmed in the LOVO colorectal cancer cell line in vitro and in tumor volume reduction of its xenograft in vivo (Russo et al., 2001) . Similarly, the role of NF-kB in radioresistance was also seen in the A172, MO54, and T94 human glioma cell lines at 1-10 Gy (Yamagishi et al., 1997; Honda et al., 2002) , the 3SB mouse lymphoma cell line exposed to 5 Gy (Kawai et al., 1999) , the UM-SCC-9 head and neck carcinoma cell line at a dose rang of 1-12 Gy (Kato et al., 2000) , the KB head and neck carcinoma cell line at 2 Gy (Didelot et al., 2001) , HeLa cells exposed to 2 Gy (Eichholtz-Wirth and Sagan, 2000), and the HK18 human keratinocyte line at 2-12 Gy (Chen et al., 2002) . These observations indicate that radiosensitization can be achieved by inhibiting NF-kB activation at the clinically relevant IR doses in many cancer cell types. Like the unresolved signaling mechanisms discussed above, the role of NF-kB in radioresistance is not straightforward and is heavily dependent on the specific cancer cell lines examined. Several studies found that alteration of NF-kB activation did not affect radiosensitivity, either positively or negatively. These include the PC3 prostate cancer and HD-MyZ Hodgkin's lymphoma cell lines (Pajonk et al., 1999 (Pajonk et al., , 2000 , the U251 glioblastoma cell line ) and the RIE-1 rat intestinal epithelial cell line (Grana et al., 2002) . Others have further implicated the lack of NF-kB-dependent radioresistance in SF539 glioblastoma, SW620 and HT29 colon carcinoma, BXPC-3 pancreatic carcinoma, and C-39A normal fibroblast cell lines .
In conclusion, activation of NF-kB by IR can be observed in different cell systems at clinically relevant doses; however, there are also cell contexts in which it is not readily observed by EMSAs. In particular, activation of NF-kB in normal tissues versus primary tumors in vivo at low-dose IR needs further evaluation. Use of different assays to detect NF-kB activation may also be required to fully appreciate the potential tissue specificity of this activation pathway in normal cells. In this context, a model developed by Carlsen et al. (2002) to directly image NF-kB activation in vivo or development of similar assay systems could be most useful. While NF-kB activation by IR can be readily observed in a wide variety of cancer cell lines in vitro, the signal transduction mechanisms are complex and likely distinct at low versus high doses of radiation. There seems to be a consensus regarding the role of NF-kB in mediating inflammatory responses to IR exposures, but its role in radiosensitization is highly dependent on the cancer cell line. Importantly, it is entirely unclear whether these in Induction of transcription factors after low doses of IR T Criswell et al vitro observations regarding the mechanisms and roles of NF-kB activation can be extrapolated into primary and metastatic tumors in cancer patients. Other studies employing 2D-versus 3D-culture systems have demonstrated that the sensitivity of specific cancer cell lines to radiation and anticancer drugs can be drastically altered by the presence of specific extracellular matrix components as well as cell polarity (Durand and Olive, 2001; Weaver et al., 2002) . More importantly, activation of NF-kB by etoposide and TNF-a was also greatly modulated by the 3D architecture of the T4-2 mammary tumor cell line (Weaver et al., 2002) . Since most of the aforementioned studies were performed under 2D conditions on plastic, it is critical to determine both the mechanisms and the roles of NF-kB activation by IR in modulation of radiosensitization under 3D culture and in vivo conditions. Even with these theoretical shortcomings, data to date are promising that NF-kB represents a novel anticancer target to enhance radiotherapy at clinically relevant doses. Such efforts have been spearheaded by multiple investigators, especially Baldwin and his colleagues Russo et al., 2001; , to enhance not only radiotherapy but also chemotherapy. One of the major questions that remain to be resolved is: What are definable mechanism(s) that explain whether NF-kB plays a positive, negative, or neutral role in modulation of radiosensitivity in specific cancer cell types in vivo? Answers to this question will undoubtedly help target specific cancer types for enhancement of radiotherapy through NF-kB modulation, but will require analyses of NF-kB activation mechanisms at clinically relevant doses of IR.
AP-1 transcription factor activation by IR
The 'activating protein-1' (AP-1) transcription factor was first identified as a protein responsible for regulating the expression of the human metallothionein promoter (Lee et al., 1987; Bohmann et al., 1988) . Using AP-1 DNA-binding-site sequence-specific chromatography, several proteins were purified suggesting that the AP-1 transcription factor was a complex of more than one protein. Subsequently, analyses identified these proteins as members of the c-Jun and c-Fos protein families that can homo-or heterodimerize. The functional AP-1 transcription activator complex was subsequently identified as containing the c-Jun, Jun-B, Jun-D, as well as c-Fos, Fos-B, FRA-1, and FRA-2 proteins (Cohen et al., 1989; Hirai et al., 1989; Wilkinson et al., 1989; Nishina et al., 1990; Redemann-Fibi et al., 1991; Suzuki et al., 1991) . Further studies identified additional binding partners (coactivators or corepressors), such as activating transcription factor-2 (ATF-2) (van Dam et al., 1993; De Cesare et al., 1995; Morooka et al., 1995; van Dam et al., 1995; Novotny et al., 1998) , Maf (Kataoka et al., 1994; Kerppola and Curran, 1994) , NRF1 (Novotny et al., 1998), and NRL (Kerppola and Curran, 1994) .
Jun proteins and their regulation
The v-Jun oncogene was first isolated from the avian sarcoma virus-17 (Jun is derived from ju-nana, the Japanese word for 17) (Maki et al., 1987) . c-Jun and a number of Jun family members were isolated from mammalian cells based on their abilities to homo-and/or heterodimerize with themselves, Fos family members, or CREB/ATF, MAF, and NRL. Various compositions of AP-1 result in differential DNA-binding affinities (e.g. c-Jun/c-Fos4c-Jun/c-Jun4Jun-D/Jun-D4Jun-B/ Jun-B), and some of these complexes can interfere with other AP-1 complexes (Hai and Curran, 1991; Ryseck and Bravo, 1991) . It was shown, for example, that Jun-B may act as either a positive or negative regulator of transcription via AP-1 site (Kobierski et al., 1991; Finch et al., 2002) . c-Jun protein is activated by phosphorylation of its N-terminal domain on residues Ser 63 and Ser
73
. Substitution of these serine residues with alanine completely inactivated the Jundependent transcription (Adler et al., 1992a) . Analyses of c-Jun activation following UV irradiation led to the cloning of c-Jun N-terminal kinase (JNK), a member of the stress-activated protein kinase (SAPK) family (Kyriakis et al., 1994) .
Fos proteins and their regulation
The Fos protein family derived its name from the Finkel-Biskis-Jenkins murine osteosarcoma virus, from which v-Fos was isolated. c-Fos is a nuclear phosphoprotein of about 55 kDa molecular weight (Giardina et al., 1987) . Fos family members are expressed predominantly in osteoblasts. c-Fos forms exclusive heterodimers with its binding partners, including the Jun family members ATF, MAF, and NRL, which are unable to form homodimers (Ransone et al., 1990; Kerppola and Curran, 1994) . As in the case of c-Jun, c-Fos transcriptional activity is thought to be regulated by phosphorylation. An enzyme called Fos kinase was isolated (Nel et al., 1994; Taylor et al., 1994) ; however, its role in the activation of AP-1 by IR has yet to be determined.
AP-1 characteristics
A common feature of proteins that form the AP-1 transcription factor is the presence of a leucine zipper that consists of heptad repeats of leucine residues aligned along one face of an alpha helix. Intercalation of leucine residues within the zippers of the two proteins and formation of a coiled-coil structure result in an AP-1 protein dimer. Basic regions adjacent to the leucine zippers serve as the DNA-binding domain of the AP-1 factor. The AP-1 binding site, also known as the TRE (12-O-tetradecanoylphorbol-b-acetate (TPA)-response element) (Lee et al., 1987) , has a palindrome consensus sequence TGA(C/G)TCA. The AP-1 site is similar to the cAMP response element (CRE): TGACGTCA. Binding of the Jun family members to the CREs either alone or in complex with ATF/CREB proteins was reported (Hai and Curran, 1991; Masquilier and Sassone-Corsi, 1992) . Many genes have AP-1 site(s) in their promoters; however, these are mostly genes that are relevant to bone biology (e.g. collagenase) and that are responsive to AP-1 induction (Auble and Brinckerhoff, 1991) . The induction of IL-6 by X-irradiation (2 Gy, 6 h) in lymphocytic cancer cell lines was shown to be at least partially dependent on AP-1 activity (Brach et al., 1993b; Kick et al., 1995) .
AP-1 activation after IR
Soon after AP-1 was discovered, elevations in the steady-state levels of c-Jun, Jun-B, and c-Fos mRNA after IR were reported (Higo et al., 1989; Sherman et al., 1990; Woloschak and Chang-Liu, 1990 ). C-Fos mRNA was induced in Syrian hamster embryo cells within 3 h after 0.75 Gy of X-rays or 0.9 Gy of gamma-rays (Woloschak and Chang-Liu, 1990 ). In contrast, no detectable c-Fos mRNA induction was observed after treatment with high-LET fission-spectrum neutrons. In separate experiments, increases in c-Jun, c-Fos, and Jun-B steady-state mRNA levels in human HL-60 human promyelocytic leukemia cells were not detected at IR doses below X5 Gy (Sherman et al., 1990) . FosB and Jun-D were also shown to increase their mRNA steadystate levels after 5 Gy of IR in HL-60 cells (Datta et al., 1992a) . Curiously, the majority of studies of induction of AP-1 components by IR have been performed on cells not related to bone tissue, where these proteins, particularly c-Fos, are supposed to have physiological significance. Furthermore, the doses of IR used were much higher than those commonly used in radiotherapy. After supralethal doses of IR, increases in c-Jun and c-Fos mRNA levels correlated with a number of detectable intracellular processes, such as transient downregulation of CDC2, cyclin A, cyclin B, and CDC25 genes (Datta et al., 1992b) , induction of IL-1 (Ishihara et al., 1993) , and apoptotic DNA fragmentation (Manome et al., 1993) . However, no direct connection between these events was shown, and no transcriptional activation of AP-1 nor direct increases of c-Fos, c-Jun, or AP-1 proteins were determined.
Responses of AP-1 components to the lower, clinically relevant doses of IR (0.25-2 Gy) and induction of AP-1 activity as a transcription factor were later shown in Epstein-Barr virus-transformed human lymphoblastoid 244B cells. Induction of c-Fos mRNA, after as low as 0.25 Gy, and c-Jun, after 0.5 Gy, was observed, and levels of these mRNAs peaked at 1 h, but decreased 4 h after IR treatment (Prasad et al., 1995) . Subsequent studies of the c-Jun promoter region, using a chloramphenicol acetyl transferase (CAT) reporter, revealed that AP-1 and CCAAT DNA elements were required for induction of this gene by high-dose IR exposures (Hallahan et al., 1996) . These data suggested that a positive feedback loop was possible in c-Jun activation following supralethal doses of IR. The requirement of AP-1 for the induction of Jun gene was further confirmed in hypoxic HeLa cells (Minet et al., 2001) . These data suggested the activation of a pre-existing AP-1 complex by IR via a post-translational mechanism(s). Indeed, the purification and cloning of JNK led to the elucidation of the c-Jun phosphorylation mechanism and AP-1 induction following various stresses, including IR (Adler et al., 1992a, b; Kyriakis et al., 1994) . Studies linking JNK activation and increased AP-1 activity after low doses of IR remain to be performed in detail.
Subsequent studies have suggested that induction of c-Jun was dependent on PKC activation. This conclusion is based on evidence that depletion of PKC by pretreatment with TPA inhibited post-IR induction of the transcription of AP-1 components c-Jun and c-Fos (Hallahan et al., 1991b) . Also, TPA was shown to induce JNK activity . A similar dependence on PKC was demonstrated for c-Fos gene induction after IR (Choi et al., 2001) . New evidence derived from the study of AT cells indicated the role of ATM in post-IR c-Jun phosphorylation and activation (Lee et al., 2001) . JNK is phosphorylated and activated by the SAPK/ERK kinase (SEK1) pathway, also known as MKK4. MKK4 is, in turn, phosphorylated by MEKK1. Activation of MEKK1 after stress could be the result of activation of p21-activated kinase (PAK) via the Rho subfamily of small GTPases, in particular Rac1 and CDC42. In fact, dominant-negative mutants of Rac1 or CDC42 inhibited JNK activation stimulated by growth factors (reviewed in Verheij et al., 1998) . It is not clear, however, whether these small GTPases participate in the IR induction of c-Jun phosphorylation. It is also yet to be determined if AP-1 activation and induction of c-Fos or c-Jun transcription via highdose IR stimulation of JNK activity occurs after low, clinically relevant doses of IR. To date, nearly all of the studies concerned with elucidation of the signal transduction mechanisms of activation of the AP-1 transcription factor have used supralethal doses of IR.
Even though activation of AP-1 after IR has been described, it is not clear that activation of this transcription factor mediates downstream genes that have functional consequences cellular responses to IR. Among the genes that have been clearly shown to be activated by AP-1 after IR are various cytokines, including TGF-b1 (Martin et al., 1997) , vascular endothelial growth factor VEGF , and IL-6 (Beetz et al., 2000) . Interestingly, none of these genes have been found to be responsive to AP-1 activation alone. In the case of TGFb, it was shown that AP-1 activation alone was, in fact, not sufficient for the induction of the gene transcript (Gault et al., 2002) . Likewise, AP-1 acts synergistically with NF-kB (Beetz et al., 2000) to induce IL-6 transcription. Clearly, cells have evolved complex mechanisms for gene induction after IR, as well as other stresses. This fact is highlighted by the failure of multiple researchers (unpublished data) to find a majority of known AP-1 transcriptionally dependent downstream genes induced in cells under conditions known to activate AP-1 after IR. Additionally, it should also be noted that AP-1 activation was not found in all cells after IR exposure (Sahijdak et al., 1994) , indicating cell specificity in this IR-responsive transcription factor and probably in JNK/SAPK/MEKK1 activation.
SP1 activation after low doses of IR
SP1 was the first identified member of a family of transcription factors composed of sixteen (16) different proteins isolated to date that bind to similar sequences in the promoter regions of human genes (Black et al., 2001) . SP1 is ubiquitously expressed in mammalian cells and binds with high affinity to GC-rich sequences called GC-boxes, and with a lower affinity to CACC-elements called GT-boxes. SP1 is thought to play a role in various cellular processes, including cell cycle regulation, chromatin remodeling, and maintenance/propagation of methylation-free CpG islands. The importance of SP1-mediated transcription is underscored by the fact that SP1-null mice are embryonic lethal by day 10. This family of transcription factors includes the SP family members (SP1, SP2, SP3, and SP4), and the Kruppellike family members. SP1 and SP3 have additional isoforms as a result of trans-splicing between premRNAs or alternative translation initiation, respectively, that add to the complexity of this family of transcription factors. Additionally, SP3 can act to repress transcription of SP1-dependent promoters by competing with SP1 for the DNA-binding site.
SP1 and SP3 are retinoblastoma (Rb) control proteins (RCPs) that bind to promoter regions, known as retinoblastoma control elements (RCEs). RCPs are regulated by the Rb protein and control induction of several immediate early growth-response genes (IEGs) after cell stress (i.e. c-Fos, c-Jun, c-Myc, and TGF-b1). Two reports have shown the inducibility of SP1 DNA binding after high doses of IR (44 Gy). Activation of SP1 DNA binding after lower doses of IR has not been investigated in detail to date, although changes in SP1 post-translational modification were observed after as little as 2 cGy IR (Criswell et al., unpublished data). Yang et al. (2000) demonstrated increased SP1-related, RCP DNA binding to an RCE in radioresistant human malignant melanoma (U1-Mel) cells after 4.5 Gy, which correlated with an increased expression of IEGs; although low doses of IR were, in general, not used in this study, exposure of U1-Mel cells to this dose of IR resulted in only 60% lethality and greater than 50% survival within the 4-h potentially lethal damage recovery period allowed. Meighan-Mantha et al. (1999) demonstrated a five-fold increase in SP1-binding activity in head and neck squamous cell carcinoma after 15 Gy. Further research needs to be done to explore the possible role(s) of SP1 and the complex RCP binding to RCEs within specific genes during cell death or survival responses after low-dose IR exposures.
IR-activation of the EGR-1 (SP1-related) transcription factor
The early growth response 1 gene (EGR-1, a.k.a., NFGI-A, KROX-24, TIS-8, or ZIF/268) product is unique among transcription factors, since both the transcription factor Nenoi et al., 2001 ) and the gene transcript (Datta et al., 1992c; Datta et al., 1993) are both activated and induced, respectively, by supralethal doses of IR. The EGR-1 gene encodes a nuclear phosphoprotein with a cysteine-histidine zincfinger motif that is homologous with the Wilms' tumor susceptibility gene and binds to the SP1-like DNA element 5 0 -CGCCCCCGC-3 0 (Cao et al., 1990; . EGR-1 belongs to a class of transcription factors that includes SP1 (Cao et al., 1992) , TFIIIA (Vrana et al., 1988) , and SW15 (Stillman et al., 1988) . Along with the reported IR inducibility of EGR-1, the gene is also reported to be induced by various mitogenic stimuli, all believed to be the result of v-SRC and v-FPS protein kinase activities (Qureshi et al., 1991; Alexandropoulos et al., 1992) .
To date, the minimum dose of IR required to induce EGR-1 transcription or activation of transcription factor binding is 5 Gy, and has been reported in a variety of cancer cell lines, including human HL-525 myeloid leukemia, U87 malignant glioma, and A375-C6 melanoma as well as in the AsPc-1 human pancreatic tumor cells (Datta et al., 1992c; Datta et al., 1993; Ahmed et al., 1996 Ahmed et al., , 1997 Takahashi et al., 1997) . Induction of EGR-1 was prevented by the free radical scavenger NAC , however, the transcription factors responsible for regulating the gene's promoter at proposed serum response elements (SREs) and/or CC(A/T) 6 GG sequences remain unexplored Ahmed et al., 1996 Ahmed et al., , 1997 Meyer et al., 2002) . Only one study has investigated the potential functional significance of EGR-1 induction on radiosensitivity, specifically using the A375-C6 melanoma cell line (Ahmed et al., 1996) . Using stable expression of an EGR-1 dominant-negative mutant, as well as transient expression of EGR-1 antisense, EGR-1 levels were diminished and the effects of these changes on radiosensitization in terms of 'percent growth inhibition' were monitored following IR (5 and 20 Gy doses were used). Rather modest effects of antisense and dominant-negative EGR-1 expression on radiosensitivity were reported. The results were interpreted to indicate that EGR-1 is required for the growthinhibitory response of these melanoma cells to IR. EGR-1 knockout studies and the use of clinically relevant doses of IR using colony-forming ability assays would be required for definitive proof of this hypothesis.
Considering that the EGR-1 promoter has been one of the few IR-inducible sequences selected for 'proof of principle' gene therapy (discussed below) for the proposed delivery of the bystander death gene, TNF-a (Wilson et al., 1993; Weichselbaum et al., 1994 Weichselbaum et al., , 2002 Hallahan et al., 1995c) , it is surprising that (a) such little information is available about the signal transduction pathways that regulate EGR-1 induction in a variety of cell types; and (b) there is a paucity of data to indicate that the EGR-1 promoter can be induced by doses of IR that would be considered relevant to clinical therapy. Analyses of the published literature revealed that only one study has examined the signaling pathways that stimulate the EGR-1 promoter at somewhat reasonable doses of IR (B5 Gy) (Meyer et al., 2002) . In this study, the ERK1/2 and SAPK/JNK signal transduction pathways were implicated, based entirely on the use of inhibitors of these specific pathways. The role of PKC was also implicated (Hallahan et al., 1991a; 1995b, c) , however, these studies utilized supralethal doses of IR to leukemic cells, and the reported results were simply not applicable to clinically relevant doses of IR. A further review of the literature indicates that not all studies have found EGR-1 induction in mammalian cells after IR, and that in some cells the induction or expression of SP1 can interfere with specific regulatory elements in the EGR-1 promoter (Nenoi et al., 2001) . In summary, stimulation of EGR-1 is observed in human cancer cells, however, supralethal doses of IR are generally required for the observed changes in transcription factor activation and induction.
Oct-1 and NF-Y transcription factors
A number of recent papers have demonstrated activation of octamer binding protein 1 (Oct-1) and/or NF-Y transcription factors in response to stress (MeighanMantha et al., 1999; Zhao et al., 2000; Bertagna and Jahroudi, 2001; Jin et al., 2001) . Most of the data reported to date have used agents other than IR, such as methylmethane sulfonate (MMS), camptothecin, etoposide, cisplatin, or UV. A significant induction of Oct-1 (fivefold), monitored by EMSAs, was observed in PCI-04A head and neck squamous cell carcinoma cells within 4 h after 5 Gy (Meighan-Mantha et al., 1999) . Similar, albeit significantly less, Oct-1-binding activity was also reported in PC-3 human prostate cancer, as well as MDA-MB-231 human breast cancer cells after 5 Gy. Activated Oct-1 binding was more rapid and prolonged (lasting 0.5-16 h post-treatment) using supralethal doses of most cytotoxic agents; for example, such responses were reported in PCI-04A cells after 20 Gy. Lower doses of IR have not been explored, and changes in promoter activity before versus after IR, using an Oct-1-dependent promoter, remains to be performed.
As with many activated transcription factors, particularly after exposure of cells to supralethal doses of IR, it is unclear as to the exact function of activated Oct-1 and/or NF-Y DNA-binding activity on gene expression. One study found simultaneous activation of Oct-1 and NF-YA DNA-binding activities were essential for the p53-independent induction of the GADD45 promoter after lethal doses of MMS (100 mg/ml) or UV (10 J/M 2 ) in HCT116 human colon carcinoma cancer cells (Jin et al., 1996) . Separate mutations within the two Oct-1-binding sites or the NF-YA CAAT box abrogated induction of the GADD45 promoter. Unfortunately, IR exposures were not examined in this study. In another study of the secretion of von Willebrand factor (VWF) after IR, activated NF-Y DNA-binding activity to a CCAAT element within the À90 to þ 22 core promoter was found to be essential for this gene's promoter activity after lethal doses of IR (Bertagna and Jahroudi, 2001 ). Since VWF is an important factor in thrombus formation, understanding the regulation of this secreted factor after IR may be very important for controlling IR-induced thrombus formation.
The activation of Oct-1 DNA binding has not been a universal property of IR-exposed cells. Sahijdak et al. (1994) found that Oct-1 levels were not altered in radioresistant human Ul-Mel melanoma cells before or after various doses of IR (2-10 Gy) compared with normal basal level DNA-binding activities using EMSAs and 50-bp oligomers containing the Oct-1-binding motif. Factors such as cell-type specificity or specific growth conditions that may affect the activation of Oct-1 or NF-Y DNA-binding activities after IR in mammalian cells have yet to be determined. Analyses in vivo of VWF and Oct-1 or NF-Y activities are also warranted.
Exploiting IR-inducible promoters and transcription factors for improved cancer therapy
Over the past 10 years or more, an extensive effort by many laboratories has attempted to understand the cellular and molecular biology of stress induced by IR. Unfortunately, most of these studies have focused on signal transduction events occurring after relatively high, clinically irrelevant doses of IR that subsequently activate transcription factors and corresponding downstream promoters (reviewed above, Table 1 ). The assumption has been that one can then extrapolate down to low doses of IR and assume that the same changes in signal transduction events, activation of transcription factors (as well as coactivators and corepressors), stimulation of specific promoters, and induction of IR-inducible gene products occur at low, clinically relevant doses of IR. This strategy has been used in an attempt to exploit the EGR-1 promoter as described above (Hallahan et al., 1995c) . To date, little success in this approach has been achieved. Overall, the accumulated literature on IR-inducible gene expression seems to indicate that a better understanding of lowdose IR-inducible promoters of specific genes in solid tumors, and not the more radiosensitive lymphocytes, is in order. More research focusing on gene induction events occurring in solid tumors (or cells from solid tumors) after IR doses between 0.5-2 Gy is needed. Extrapolation from high (many times supralethal) doses of IR to clinically relevant exposures may often be misleading.
Examination of the literature indicates that two transcription factors, p53 and NF-kB, are reproducibly responsive (Zhan et al., 1993; Smith et al., 1994; Bae et al., 1995; Bae et al., 1996; Fornace et al., 1999 Fornace et al., , 2002 Goldwasser et al., 1999; Sheikh and Fornace, 2000a, b) to clinically relevant (and sometime lower) doses of IR. These data suggest that promoters regulated by these transcription factors (e.g. the p21-or 3X-kB-containing promoters) may be useful for IR-inducible expression in gene therapy regimen. For example, Ueda et al. (2001) used the NF-kB-responsive c-IAP2 promoter to drive the expression of the proapoptotic BAX gene to induce cell death at 2 Gy. More research is needed to explore IR-inducible RCPs and RCE-directed promoters. Since these transcription factors are activated under conditions where cells survive and recover after IR, more extensive analyses of their induction and signal transduction pathways are warranted.
